DARA BioSciences, Inc. (Nasdaq:DARA) announced that five new patents were granted in the United States, Asia and Israel for its drug development programs, including lead drug candidates KRN5500 and DB959. These grants represent a total gain of 20 new U.S. and foreign patents in 2011.

SLXP, Salix Pharmaceuticals, Ltd.

** On its third quarter fiscal 2011 results, SLXP posted total product revenue of $146.2 million, an 81% increase year over year.

SLXP is increasing its estimate of 2011 total product revenue to approximately $535 million, which represents 59% growth over 2010 revenue.

DARA BioSciences, Inc. is a Raleigh, North Carolina based development-stage Biopharmaceutical Company that acquires promising therapeutic small molecules and develops them through proof of concept in humans for subsequent sale or out-licensing to larger pharmaceutical companies.

DARA BioSciences reported today that SurgiVision, Inc., a privately held company, and Brainlab AG, announced on April 11 a collaboration aimed at integrating SurgiVision’s ClearPoint(R) product line with Brainlab’s iMRI product line, with particular focus on local delivery of drugs and other therapeutic agents to precision targets in the brain under magnetic resonance imaging (MRI) guidance.